## **Core Concept**
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of immunotherapy that involves genetically modifying a patient's T-cells to recognize and attack cancer cells. This treatment approach targets specific antigens on cancer cells, making it a type of targeted therapy. CAR-T cell therapy has shown significant promise in treating certain types of blood cancers.

## **Why the Correct Answer is Right**
The correct answer, , involves cancers that are known to be effectively treated with CAR-T cell therapy. This therapy is particularly effective against B-cell malignancies because it targets the CD19 antigen, which is present on the surface of B cells. By targeting CD19, CAR-T cells can selectively kill B-cell lymphoma and leukemia cells while sparing normal T cells and other non-B cells. The mechanism involves the extraction of T cells from the patient, genetic modification to express a CAR that recognizes CD19, and reinfusion of these CAR-T cells back into the patient.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While CAR-T cell therapy is primarily known for its application in hematological malignancies, option A does not specify a cancer type that is commonly associated with CAR-T therapy.
- **Option B:** This option might seem plausible but does not accurately represent the primary indication for CAR-T cell therapy.
- **Option C:** Similar to option A, this does not accurately reflect the main use of CAR-T cells.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that CAR-T cell therapy is primarily used for treating **relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)** and **diffuse large B-cell lymphoma (DLBCL)**. A significant side effect of this therapy is **cytokine release syndrome (CRS)**, a potentially life-threatening condition that results from the rapid proliferation and activation of CAR-T cells.

## **Correct Answer: D. **